COSCIENS Biopharma Inc. Equity And Liabilities
COSCIENS Biopharma Inc. (CSCIF) had Equity And Liabilities of $21.43 million as of 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Notes
ifrs-full:EquityAndLiabilities · last filed 2026-03-25
- 2025-12-31: Equity And Liabilities $21.43M.
- 2025-09-30: Equity And Liabilities $23.86M.
- 2025-06-30: Equity And Liabilities $27.56M.
- 2025-03-31: Equity And Liabilities $31.14M.
| Period end | Equity And Liabilities | Equity And Liabilities as first filed |
|---|---|---|
| 2025-12-31 | $21.43M 20-F · filed 2026-03-25 | |
| 2025-09-30 | $23.86M 6-K · filed 2025-11-12 | |
| 2025-06-30 | $27.56M 6-K · filed 2025-08-14 | |
| 2025-03-31 | $31.14M 6-K · filed 2025-05-13 | |
| 2024-12-31 | $35.07M 20-F · filed 2026-03-25 | |
| 2024-09-30 | $43.77M 6-K · filed 2024-11-12 | |
| 2024-06-30 | $50.05M 6-K · filed 2024-08-13 | |
| 2024-03-31 | $31.79M 6-K · filed 2024-05-16 | |
| 2023-12-31 | $23.75M 20-F · filed 2025-04-09 | $37.02M 20-F · filed 2024-03-27 |
| 2023-09-30 | $42.49M 6-K · filed 2023-11-09 | |
| 2023-06-30 | $46.48M 6-K · filed 2023-08-09 | |
| 2023-03-31 | $51.28M 6-K · filed 2023-05-09 | |
| 2022-12-31 | $56.03M 20-F/A · filed 2024-07-17 | |
| 2022-09-30 | $66.61M 6-K · filed 2022-11-03 | |
| 2022-06-30 | $71.83M 6-K/A · filed 2022-08-04 | |
| 2022-03-31 | $76.34M 6-K · filed 2022-05-11 | |
| 2021-12-31 | $80.10M 20-F/A · filed 2024-02-15 | |
| 2021-09-30 | $82.04M 6-K · filed 2021-11-04 | |
| 2021-06-30 | $84.35M 6-K · filed 2021-08-05 | |
| 2021-03-31 | $87.01M 6-K · filed 2021-05-05 | |
| 2020-12-31 | $37.01M 20-F · filed 2022-03-29 | $37.28M 40-F · filed 2021-03-25 |
| 2020-09-30 | $32.27M 6-K · filed 2020-11-05 | |
| 2020-06-30 | $17.67M 6-K · filed 2020-08-06 | |
| 2020-03-31 | $19.64M 6-K/A · filed 2020-05-11 | |
| 2019-12-31 | $19.98M 40-F/A · filed 2021-03-29 | |
| 2019-09-30 | $21.50M 6-K · filed 2019-11-07 | |
| 2019-06-30 | $20.75M 6-K · filed 2019-08-13 | |
| 2018-12-31 | $25.01M 20-F · filed 2020-03-31 | |
| 2017-12-31 | $22.20M 20-F · filed 2019-04-01 | |
| 2016-12-31 | $31.66M 20-F · filed 2018-03-28 |